An inhibitor of MEK, trametinib, in combination with ATRA restored the sensitivity of ATRA-resistant AML cell lines to ATRA by enhancing the protein levels of STAT3 and phosphorylation of Akt or JNK, and STAT3, PI3K, and JNK inhibitors all inhibited trametinib + ATRA induced cell differentiation in AML cell lines (Lu et al., 2021). Here, AKT1 is linked to acute myeloid leukemia.